Keith C. Bible, MD, PhD, medical oncologist, Mayo Clinic, discusses the impact that lenvatinib (Lenvima) has had on the treatment landscape of differentiated thyroid cancer.
Keith C. Bible, MD, PhD
Advertisement
Articles by Keith C. Bible, MD, PhD
Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the promise of pemetrexed and carboplatin as a potential treatment option for patients with follicular cell-derived thyroid cancers.
Advertisement
Latest Updated Articles
Dr. Bible on Impact of Lenvatinib on Treatment Landscape of DTCFebruary 19th 2016
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Targeted Therapies, Frontline Combos Headline Key Lung Cancer Data to Emerge From ASCO 2026
4
CARTITUDE-4 Analysis Shows Bridging Therapy Response Predicts Cilta-Cel Benefit in Lenalidomide-Refractory Myeloma
5